1. Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2019. doi: 10.1016/j.semcancer.2019.06.001
2. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T, Negishi E, Harada M, Yoshida S, Matsumura Y. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. J Control Release. 2020, 4;323, 138-150. doi: 10.1016/j.jconrel.2020.03.048
3. Numasawa K, Hanaoka K, Saito N, Yamaguchi Y, Ikeno T, Echizen H, Yasunaga M, Komatsu T, Ueno T, Miura M, Nagano T, Urano Y. A Fluorescent Probe for Rapid, High-Contrast Visualization of Folate-Receptor-Expressing Tumors In Vivo. Angew Chem Int Ed Engl. 2020, 59, 6015-6020, doi: 10.1002/anie.201914826
4. Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Mol Cancer Ther. 2019, 8, 2043-2050, doi: 10.1158/1535-7163
5. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models. Cancer Sci. 2019, 110, 3296-3305, doi: 10.1111/cas.14146
6. Manabe S, Yamaguchi Y, Matsumoto K, Fuchigami H, Kawase T, Hirose K, Mitani A, Sumiyoshi W, Kinoshita T, Abe J, Yasunaga M, Matsumura Y, Ito Y. Characterization of antibody products obtained through enzymatic and non-enzymatic glycosylation reactions with a glycan oxazoline and preparation of homogeneous antibody-drug conjugate via Fc N-glycan. Bioconjug Chem. 2019, 30, 1343-1355, doi: 10.1021/acs.bioconjchem.9b00132
7. Sugyo A, Aung W, Tsuji AB, Sudo H, Takashima H, Yasunaga M, Matsumura Y, Saga T, Higashi T. Anti-tissue factor antibody-mediated immuno-SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Oncol Rep. 2019, 41, 2371-2378, doi: 10.3892/or.2019.7017
8. Asano R Hosokawa K, Taki S, Konno S, Shimomura I, Ogata H, Okada M, Arai K, Nakanishi T, Onitsuka M, Omasa T, Umetsu M, Kumagai I. Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats. Sci Rep. 2020, 10, 4913, doi: 10.1038/s41598-020-61840-3
9. Hemmi S, Asano R, Kimura K, Umetsu M, Nakanishi T, Kumagai I, Makabe K. Construction of a circularly connected VHH bispecific antibody (cyclobody) for the desirable positioning of antigen-binding sites. Biochem Biophys Res Commun. 2020, 26, 72-77, doi: 10.1016/j.bbrc.2019.12.018
10. Ueda A, Umetsu M, Nakanishi T, Hashikami K, Nakazawa H, Shuhei H, Asano R, Kumagai I. Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. Int J Mol Sci. 2020, 21, 711, doi: 10.3390/ijms21030711